EUCTR2016-001493-15-FR进行中（未招募）1 期
A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy: SULTAN (improving SUrgery of Liver metastases: a Trial of the Arterial chemotherapy Network). - SULTA
ICANCER0 个研究点目标入组 140 人开始时间: 2017年10月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Histologically confirmed colorectal cancer (CRC), and radiologic or histologic proof of CRLM
- •not amenable to a curative intent-treatment after two months to 6 months of first-line induction CT
- •2.First-line CT with oxaliplatin and/or irinotecan combined with a fluoropyrimidine and a targeted therapy (e.g., anti-EGFR or antiangiogenic antibody) for metastatic disease (patients ending their adjuvant chemotherapy after primary tumor resection since less than 6 months should also have received first-line chemotherapy for metastatic disease)
- •3.Unresectability of the CRLM will be confirmed by a centralized multidisciplinary expert panel (composed of surgeons, radiologists, interventional radiologists and medical oncologists). The panel will review the CT scan and MRI of the patients (weekly web conference). Non-resectability criteria (one of the following criteria):
- •-Upfront R0/R1 resection of all CRLM (that leaves at least two adequately perfused and drained segments) is not possible
- •-and/or metastases in contact with major vessels of the remnant liver which would require resection of the vessel for an R0 resection (i.e., tumor involvement of main portal right and left portal veins, of the three main hepatic veins, or of the retrohepatic vena cava)
- •-and/or documented progressive disease on imaging (according to the RECIST v1.1 criteria) or doubling of serum levels of carcinoembryonic antigen (CEA) or CA 19.9 following = 2 months of induction CT
- •4.At least one measurable liver metastasis according to the RECIST v1.1
- •5.Age = 18 years
- •6.ECOG performance status 0-1
- •7.Normal liver function, i.e. bilirubin < 1.5 times the upper limit of normal values (ULN), aminotransferases < 5 ULN, alkaline phosphatase < 5 ULN
- •8.International normalized ratio (INR) < 1.5 ULN
- •9.Neutrophils > 1500/mm3, platelets > 100 000/mm3, hemoglobin > 9 g/dL (transfusion allowed)
- •10.Calculated creatinine clearance > 50 mL/min (Cockcroft and Gault formula)
- •11.Informed consent signed by the patient or his/her legal representative
- •12.Patient affiliated to a social security regimen
- •13.Adequate contraception if applicable
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •NON-INCLUSION CRITERIA:
- •1. Patient eligible for curative-intent treatment of CRLM (i.e. resection and/or thermoablation), according to the local multidisciplinary team and/or the central review.
- •2. Extrahepatic tumor disease (except = 3 lung nodules < 10 mm deemed amenable to curative-intent resection/thermoablation and non-resected primary tumor with no or mild symptoms)
- •3. Patient with contraindication for trial drugs (investigators have to refer to drugs SmPC, see appendix 1); contraindication limited to targeted therapy (e.g., anti-EGFR or antiangiogenic antibody) is not an exclusion criteria
- •4. Sensory neuropathy = grade 2 (NCI-CTAE v.4.0)
- •5. Significant chronic liver disease (resulting in portal hypertension and/or liver insufficiency)
- •6. Allergy to contrast media that cannot be managed with standard care
- •7. Previous organ transplantation, HIV or other immunodeficiency syndromes
- •8. Concomitant or past history of cancer within 5 years prior to entry into the trial other than adequately treated basal-cell skin cancer or in situ carcinoma of the cervix
- •9. Concomitant medications/comorbidities that may prevent the patient from receiving study treatments as uncontrolled intercurrent illness (for instance: active infection, active inflammatory disorders, inflammatory bowel disease, intestinal obstruction, symptomatic congestive heart failure, uncontrolled hypertension…)
- •10. Ionic disorders as:
- •Kalemia = 1 x ULN
- •Magnesemia < 0.5 mmol/L
- •Calcemia < 2 mmol/L
- •11. Patient with known dihydropyrimidine dehydrogenase deficiency
- •12. QT/QTc > 450 msec for men and > 470 msec for women
- •13. Concomitant intake of St. John's wort
- •14. Patient already included in another clinical trial with an experimental treatment
- •15. Pregnancy or lactation
- •16. Patients deprived of liberty or under guardianship
- •17. Patients unable to undergo medical monitoring test for geographical, social or psychological reasons
研究者
相似试验
招募中
2 期
A randomized controlled phase 2 trial comparing the safety and usefulness of robot-assisted esophagectomy and thoracoscopicJPRN-jRCT1040220153Takeuchi Hiroya90
招募中
2 期
AFP peptides after TACEHepatocellular carcinomaJPRN-jRCT2041220154Mizukoshi Eishiro84
未知
不适用
A randomized phase II study designed to compare toxicity and dose intensity between four-week versus three-week schedule of gemcitabine for advanced pancreatic cancerAdvanced nonresectable pancreatic cancerJPRN-UMIN000000974Okayama University Hospital90
进行中（未招募）
1 期
A randomized comparative phase II trial evaluating the capacity of the dualcombination doravirine/raltegravir to maintain virological success in HIV-1infected patients with an HIV-RNA plasma viremia below 50 copies/mL under acurrent antiretroviral regimen.HIV-1 INFECTIONEUCTR2019-004195-19-ITCentre de Recherche et d’Etudes sur la Pathologie Tropical et le Sida (CREPATS)150
进行中（未招募）
1 期
A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma viremia below 50 copies/mL under a current antiretroviral regimeEUCTR2019-004195-19-FRCentre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS)150